[Thromboxane A2 receptor antagonist in asthma therapy].

Article Details

Citation

Copy to clipboard

Endo S, Akiyama K

[Thromboxane A2 receptor antagonist in asthma therapy].

Nihon Rinsho. 1996 Nov;54(11):3045-8.

PubMed ID

8950952 [ View in PubMed

]

Abstract

Lung tissues produce a large amount of Thromboxane (Tx) A2. In addition to platelet aggregation and artery smooth muscle contraction, TxA2 strongly induces airway smooth muscle contraction and bronchial hyperresponsiveness. Not only TxA2, but many arachidonate cyclooxygenase metabolites such as PGD2, PGF2 alpha, PGH2, and others stimulate TP (PGH2/TxA2) receptor and can take a pathophysiological role for bronchial asthma. Several compounds competitively antagonizing TP receptor have been developed and being proved to have beneficial effects for treating of bronchial asthma in clinical. In this review the efficacy and usage of TP receptor antagonists for bronchial asthma was discussed.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Seratrodast	Thromboxane A2 receptor	Protein	Humans	Unknown	Antagonist	Details